Avomira 25mg Tablet ER
Marketer
Micro Labs Ltd
Salt Composition
Mirabegron (25mg)
Overview Avomira 25mg Tablet ER
Extended-release Avomira 25mg tablets alleviate overactive bladder symptoms such as urinary urgency, frequency, and incontinence. This medication relaxes bladder muscles, improving urinary storage capacity. Always follow your doctor's prescribed dosage and duration for Avomira 25mg ER tablets; it can be taken with or without food. Swallow the tablet whole; do not crush or chew. Discontinue use only after consulting your physician, as abrupt cessation may worsen symptoms. Complete the prescribed treatment course for optimal results. Potential side effects include constipation, headache, hypertension, nasal congestion, urinary tract infection, tachycardia, and arthralgia. Report any persistent or bothersome side effects to your doctor immediately. Before starting treatment, disclose all current medications and pre-existing health conditions, including pregnancy or breastfeeding. Patients with hepatic or renal impairment require careful monitoring and regular check-ups as directed by their physician.
Primary Ingredients of Avomira 25mg Tablet ER
No text provided. Please provide the text you want me to rephrase.
Uses of Avomira 25mg Tablet ER
Managing symptoms associated with overactive bladder
Major Benefits of Avomira 25mg Tablet ER:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Avomira 25mg Extended-Release Tablet whole; avoid chewing, crushing, or breaking it. While you can take it with or without food, consistency is key—take it at the same time each day.
Common Side effects of Avomira 25mg Tablet ER:
- Constipation
- Headache
- High blood pressure
- Nasal inflammation
- Urinary tract infection
- Fast heart rate
- Joint pain
How to use Avomira 25mg Tablet ER:
Administer Avomira 25mg Extended-Release tablets precisely as your physician directs, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consumption with or without food is acceptable, however, consistent daily timing is recommended.
How Avomira 25mg Tablet ER works:
Avomira 25mg Extended-Release tablets contain a beta-3 adrenergic agonist. This medication acts by stimulating bladder receptors, resulting in bladder muscle relaxation and reduced urinary frequency, urgency, and incontinence.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when using Avomira 25mg Extended-Release Tablets with alcohol. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The extended-release Avomira 25mg tablet may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential benefits against risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Avomira 25mg tablets are likely unsafe for breastfeeding mothers. Available evidence from humans indicates potential drug transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Avomira 25mg Extended-Release tablets.
KidneyCAUTION
Extended-release Avomira 25mg tablets require careful administration in individuals with advanced renal impairment. Dosage modification of Avomira 25mg extended-release tablets may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should use Avomira 25mg Extended-Release tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. Avomira 25mg Extended-Release tablets are contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Avomira 25mg Tablet ER :
Should you forget a dose of Avomira 25mg Extended-Release Tablet, take it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Avomira 25mg Tablet ER
| Label | Value |
|---|---|
| Chemical Category | Anilide-based compound |
| Developing Habits | No. |
| Treatment Category | Urological Care |
| Action Class | Beta-3 agonist for bladder control |






